Luis Patino Duran, MD
Child & Adolescent Psychiatry · Cincinnati, OHNPI 1780923169
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $712 of the $1,153 with a category attached, or 61.7%. Every reported general payment came from a single manufacturer, Pfizer.
Across 3 payments — averaging $384.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
Across 148 payments — averaging $4403.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$495K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$90K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66K
What the payments were for
- Travel & lodging$71262%
- Food & beverage$44238%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $1,153 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEODON$1,153
How this compares
$1,153 in reported general payments places this provider in the 80th percentile of 160 child & adolescent psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 14 | $45,536 |
| SpravatoEsketamine Hcl | 26 | $43,981 |
| CaplytaLumateperone Tosylate | 13 | $20,218 |
| DayvigoLemborexant | 23 | $7,263 |
| Prazosin Hcl | 28 | $1,801 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $1,736 |
| Guanfacine Hcl ErGuanfacine Hcl | 19 | $1,286 |
| Aripiprazole | 28 | $857 |
| Clonazepam | 35 | $622 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $591 |
| Duloxetine Hcl | 31 | $567 |
| Bupropion XlBupropion Hcl | 21 | $435 |
| Buspirone Hcl | 13 | $378 |
| Zolpidem Tartrate | 16 | $165 |
| Topiramate | 15 | $139 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Cincinnati
- Melissa DelbelloCincinnati$36K
- Craig EricksonCincinnati$9K
- Ethan MusgraveCincinnati$3K
- Jonathan GarrisonCincinnati$1K
- Ernest PedapatiCincinnati$1K
- Joseph CresciCincinnati$911
- Hilton RodriguezCincinnati$649
- Janice SingermanCincinnati$360
- Mark JohnsonCincinnati$336
- Susan MerwinCincinnati$290
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.